BC Innovations | Aug 29, 2019
Product Development

Pharmas want ICH to streamline toxicity requirements for severe diseases

Pharmas have embarked on the long road to developing new ICH guidelines that could expedite patient access to therapies for severe or life threatening diseases by up to three years, calling upon advanced cancer guidance...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | Dec 23, 2017
Regulation

Prioritizing preferences

The realization that patients have distinct preferences about the trade-offs and risks inherent in medical decisions -- and that their choices are frequently different from those physicians or regulators would make -- has mobilized FDA,...
BC Innovations | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Forkhead box R2 (FOXR2)

Cancer INDICATION: Breast cancer; cancer Patient sample and mouse studies suggest inhibiting FOXR2 could help treat cancer. In human breast, lung and liver cancer cell lines, FOXR2 protein was highly expressed compared with levels in...
BioCentury | Mar 21, 2016
Emerging Company Profile

Targeting toxicity

Novonco Therapeutics Inc. is developing a pipeline of targeted cancer therapies that were designed at City of Hope and University of California Irvine to be less toxic than either first-generation inhibitors, or parent molecules. Its...
BC Innovations | Jul 23, 2015
Distillery Therapeutics

Therapeutics: Ribonucleotide reductase M1 (RRM1; R1); ribonucleotide reductase M2 (RRM2; R2)

Cardiovascular disease INDICATION: Heart failure Pig studies suggest RRM1 and RRM2 gene therapy could help treat heart failure. In a minipig model of heart failure, intracoronary infusion of an adeno-associated virus (AAV) serotype 6 (AAV6)...
BC Innovations | Jul 9, 2015
Distillery Techniques

Techniques: High throughput chromatographic assay for measuring protein binding intensity

Assays and screens TECHNOLOGY: Binding assays A high throughput method could determine binding affinities between globular protein domains and linear peptide ligands. The method co-incubated globular domains from proteins and resin saturated with peptide ligands...
BC Innovations | Apr 30, 2015
Distillery Techniques

Techniques: PK/PD model for predicting efficacy of small molecule inhibitors

Drug properties TECHNOLOGY: Pharmacokinetics/Pharmacodynamics A PK/PD model that incorporates compound-target kinetics could help predict the in vitro and in vivo efficacy of small molecule inhibitors. Kinetic values for an inhibitor-target complex, such as the rate...
BC Innovations | Apr 30, 2015
Translation in Brief

Residential predictions

Researchers at AstraZeneca plc and Stony Brook University have developed a PK/PD model that incorporates how long a drug sits on its target - its residence time - to predict the efficacy and safety of candidate compounds....
BC Innovations | Mar 19, 2015
Distillery Techniques

Techniques: Models to predict methionine oxidation in therapeutic proteins

Other TECHNOLOGY: Computational models Two computational models for predicting rates of methionine oxidation - a major route of protein degradation - could guide the engineering or formulation of therapeutic proteins. To predict methionine oxidation rates, one model...
Items per page:
1 - 10 of 73